Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 05, 2020

SELL
$5.43 - $9.22 $74,684 - $126,811
-13,754 Closed
0 $0
Q3 2019

Nov 01, 2019

BUY
$7.47 - $10.76 $102,742 - $147,993
13,754 New
13,754 $103,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $878M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Ibex Investors LLC Portfolio

Follow Ibex Investors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ibex Investors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ibex Investors LLC with notifications on news.